Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
puveitinib
- Development stage
- Unknown
- Lead developer
- Hangzhou Derun Yucheng Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Puveitinib (DR-106) is an orally bioavailable, small molecule multi-kinase inhibitor developed by Hangzhou Derun Yucheng Biotechnology. It is designed to simultaneously target three critical pathways in oncology: angiogenesis, tumor cell proliferation, and the immune microenvironment. Specifically, puveitinib inhibits Vascular Endothelial Growth Factor Receptors (VEGFR 1/2/3), Fibroblast Growth Factor Receptors (FGFR 1/2/3), and the Colony-Stimulating Factor 1 Receptor (CSF-1R). By blocking VEGFR and FGFR, the drug suppresses tumor-associated blood vessel formation and direct oncogenic signaling. Its inhibition of CSF-1R is intended to deplete or reprogram immunosuppressive tumor-associated macrophages (TAMs), thereby enhancing the anti-tumor immune response. Puveitinib is currently in Phase 1 clinical development for the treatment of advanced solid tumors.
- Other names
- DR-106DR106DR 106
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on puveitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on puveitinib.